GlassScriptPhysician profile
Michael Wade Jones
NPI 1801987847
$158,815.98
in general payments reported to CMS, 2019-2025
15 companies · $28K in 2025
The $28K reported for 2025 was more than what 88% of Obesity Medicine (Family Medicine) providers received nationally (typical 2025 total: $183).
See the full distribution for Obesity Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.76 · 2021: $95.79 · 2022: $65K · 2023: $22K · 2024: $44K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $73K · Travel and Lodging: $18K · Food and Beverage: $2,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,955.89 |
| Travel and Lodging | $18,157.70 |
| Food and Beverage | $2,205.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $157,990.76 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $102.59 | 2020-2023 | Lyumjev, Baqsimi, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.79 | 2021 | |
| Xeris Pharmaceuticals, INC. | $79.97 | 2022-2023 | Gvoke Hypopen |
| Medtronic, INC. | $79.07 | 2022-2025 | Affera Mapping System |
| Recordati_rare_diseases_inc. | $73.06 | 2022 | |
| Tandem Diabetes Care, INC. | $64.39 | 2022 | |
| Embecta Corp. | $61.29 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Bayer Healthcare Pharmaceuticals INC. | $56.01 | 2022 | |
| Grt US Holding, INC. | $45.98 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $44.78 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $36.95 | 2022-2023 | Imcivree |
| Mannkind Corporation | $36.58 | 2022-2023 | Afrezza |
| Abbott Laboratories | $24.87 | 2022 | |
| Corcept Therapeutics | $23.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.